The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Durham non-profit among several to receive funding from GSK Denzel Washington rails against American politics: ‘You’re being ...

GSK collaborates closely with Canadian sites — such as hospitals and other health-care centres — to operationalize its trials ...

Durham Success Summit started five years ago and now many of the young men from the program have new careers outside Durham.

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...